Status:
COMPLETED
Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
Sumitomo Pharma America, Inc.
Conditions:
Mucociliary Clearance
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether lung mucociliary clearance (MCC) can be significantly enhanced in healthy subjects by one week of inhalation of nebulized levalbuterol aerosol, as com...
Detailed Description
In healthy lungs, inhaled insoluble material such as bacteria, viruses, antigens, and toxins deposit in the tracheobronchial airway mucus and are removed from the lung in a matter of hours by mucocili...
Eligibility Criteria
Inclusion
- non-smoking males and non-pregnant females greater than or equal to 18 years of age
- forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) greater than or equal to 80% of predicted values
- normal systolic and diastolic blood pressures
Exclusion
- history of heart disease, irregular heartbeat, hypertension
- history of diabetes, hyperthyroid
- history of pneumonia, tuberculosis
- history of seizure disorder, depression, hospitalization in the last month for non-elective purposes, cold or flu in the previous three months
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00325767
Start Date
May 1 2004
End Date
September 1 2005
Last Update
May 15 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eudowood Division of Pediatric Respiratory Sciences
Baltimore, Maryland, United States, 21287